TITLE
Acquired Resistance to the Second-Generation Androgen Receptor Antagonist Enzalutamide in Castration-Resistant Prostate Cancer

ORGANISM
Homo sapiens

SUMMARY
Illumina gene array analyses of prostate cancer cell lines that had acquired resistance to Enzalutamide (MDV3100).

DESIGN
mRNA analyses of four cell lines (CWR-R1, LAPC-4, LNCaP, and VCAP) cells that were either untreated, treated for 48hrs with Enz (short-term), or continuously grown in Enzalutamide for > 6 months.

PLATFORM
GPL10558 Illumina HumanHT-12 V4.0 expression beadchip

CITATIONS
27036029

